FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary…
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment
- MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease
- MAVENCLAD demonstrated significant efficacy across key measures of disease activity
- Approval is based on clinical program consisting of more than9,500 patient years of cladribine data and up to 8 years of time on study
Not intended for U.S. or U.K.!-->…